MET and non-small cell lung carcinoma: Currently, a variety of targeted drugs have been developed for NSCLC targeting EGFR mutations and MET exon14 alterations, among which, drugs targeting EGFR mutations are mainly classified into two major classes: small molecule tyrosine kinase inhibitors (TKI) and monoclonal antibodies, and the TKI class mainly includes Gefitinib, Erlotinib, Afatinib, Osimertinib, Dacomitinib, Lcotinib, and Brigatinib, among others, monoclonal antibodies are comparatively rare and mainly include Necitumumab, Amivantamab, and Ramucirumab, of which Amivantamab targets the EGFR exon20 insertion [49].